An observational study in Acute Kidney Injury, Kidney Failure, Acute and Kidney Failure, sponsored by Antalya Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Antalya Health Sciences University · Observational
Among 90 studies in Acute Kidney Injury with a site in Turkey — 22 open to participants now, 23 under way, none of them phase 3. Acute Kidney Injury · Turkey.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 31st largest by planned enrollment of the 73 observational ones, is one of 18 that started in 2026, is one of 73 observational ones, reaches primary completion later than 9 of the 22 other live ones, and was the 81st registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.
This study's planned enrollment of 150 is close to the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →22 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 230 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 36 (16%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →90 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 18 started in 2026.
Median enrollment 108 across the 17 interventional studies, 130 across the 73 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
5 of 90 have an industry lead sponsor. The 10 most frequent:
Antalya Health Sciences University is the lead sponsor of 18 studies on the registry; 10 are open to participants now.
Antalya Health Sciences University has 2 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
14 of the studies in Acute Kidney Injury with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07765030Antalya Health Sciences UniversityClinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department | 2026-11-01 |
| NCT07459413Gaziosmanpasa Research and Education HospitalOral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED | 2026-11-07 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07635160Istanbul University - CerrahpasaAssessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery | 2027-01-07 |
| NCT07918742Istanbul University - CerrahpasaDiastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy | 2027-01-31 |
Among the 90 studies in Acute Kidney Injury with a site in Turkey, from their registry updates:
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Emergency renal replacement therapy may be required in critically ill patients with life-threatening conditions such as severe hyperkalemia, refractory metabolic acidosis, fluid overload or pulmonary edema, uremic complications, acute kidney injury, acute deterioration in patients with chronic kidney disease, sepsis-associated renal dysfunction, cardiorenal syndrome, or selected intoxications. In routine clinical practice, these patients are generally managed in intensive care settings. However, when intensive care capacity is limited or transfer to the hospital dialysis unit is not clinically feasible, renal replacement therapy may need to be initiated and continued in an emergency department critical care area.
This single-center, retrospective, observational, descriptive-analytical study will review the medical records of critically ill adult patients who received hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Data will be obtained from the hospital information management system, electronic medical records, laboratory records, clinical follow-up notes, renal replacement therapy records, and discharge summaries.
The study will characterize the clinical profile of patients requiring emergency renal replacement therapy and examine treatment indications, treatment modality, treatment course, pre- and post-treatment laboratory findings, treatment-related complications, and in-hospital clinical outcomes. Renal replacement therapy indications will be evaluated under predefined clinical categories, and patients with more than one indication may be classified in more than one category. Laboratory changes, particularly in potassium, pH, bicarbonate, urea, creatinine, and lactate, will be assessed using available routine clinical measurements before and after treatment.
The study is intended to provide descriptive and exploratory evidence regarding the use of HD and CVVHDF in critically ill patients managed in the emergency department and to contribute to the evaluation of emergency critical care processes in settings where intensive care capacity may be limited. No study-specific intervention will be performed, and all analyses will be based exclusively on routinely collected retrospective clinical data.
The study population will consist of critically ill adult patients aged 18 years or older who were managed in the critical care area of the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026, and who underwent emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF). All eligible patients meeting the predefined inclusion and exclusion criteria during the study period will be included using a census sampling approach. Data will be obtained retrospectively from the hospital information management system, electronic medical records, laboratory records, renal replacement therapy records, and clinical follow-up notes. No direct participant recruitment or contact will occur.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Critically ill adult patients who underwent hemodialysis (HD) in the emergency department for an emergency renal replacement therapy indication during the study period.
Procedure: Hemodialysis (HD) · Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)
Critically ill adult patients who underwent continuous venovenous hemodiafiltration (CVVHDF) in the emergency department for an emergency renal replacement therapy indication during the study period.
Procedure: Hemodialysis (HD) · Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)
Hemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
Continuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
In-Hospital Mortality
Number and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).
Time frame: Up to 30 days from emergency department admission
Emergency Department Mortality
Number and proportion of patients who die during their emergency department stay.
Time frame: Up to 1 day from emergency department admission
Intensive Care Unit Admission
Number and proportion of patients requiring admission to an intensive care unit following emergency renal replacement therapy.
Time frame: Up to 1 day from emergency department admission
Renal Replacement Therapy-Related Complications
Number and proportion of patients experiencing complications during renal replacement therapy, including hypotension, arrhythmia, cardiac arrest, bleeding, catheter-related problems, or device/technical problems.
Time frame: Up to 8 hours from emergency department admission
Plan to share: No — Individual participant data will not be shared because the study is based on retrospective clinical records containing sensitive patient information. Only anonymized, aggregated study results will be reported.
Start is estimated for Aug 2026; primary completion for Nov 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Antalya Health Sciences University